MMRN1 and cancer: Exploring ECM components, receptors, and associated signaling molecules as biomarkers for prognosis and/or therapeutic targets and treating cancer by using combinations of ECM targeting with RTK inhibitors or immunooncology drugs are promising approaches [51].